Puma Biotechnology, Inc.

Puma Biotechnology, Inc.

Puma Biotechnology, Inc.

Overview
Date Founded

2010

Headquarters

2711 Centerville Road,Suite 400,Wilmington, DE 19808

Type of Company

Public

Employees (Worldwide)

160

Industries

Pharmaceuticals
Medical Support Services
Biotechnology

Company Description

Puma Biotechnology, Inc. is a development stage biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. The company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. Puma Biotechnology was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

Executives & Employees

Chief Commercial Officer

Chief Medical & Scientific Officer

Treasurer & Senior Vice President-Finance & Administration

Senior Director, Investor Relations

Senior Director

Controller

Director

Director

Director

Subscribe now to see full list of current and former executives
Board of Directors

Founder at Puma Biotechnology, Inc.

Co-Founder at Avidity Biosciences LLC

Managing Member at Drayton Investments LLC

Senior Vice President & Chief Medical Officer at Constellation Pharmaceuticals, Inc.

Subscribe now to see full list of current and former board members
Paths to Puma Biotechnology, Inc.
Potential Connections via
Relationship Science
You
Puma Biotechnology, Inc.
Owners & Shareholders
Details Hidden

Partner Fund Management (PFM) generally uses bottom-up analysis to identify trends, investment themes and core investment opportunities across asset classes and geographies in a wide range of investment instruments. The firm may invest in various industries or sectors, including, but not limited to, communications and media, consumer, energy, financials, healthcare, industrials, materials, technology and utilities. Their main investment strategies include diversified global and healthcare. PFM seeks to identify out- and under-performing companies that have the widest expectation gaps relative to consensus. In some cases, they may apply a catalyst-driven investment approach to express their fundamental view with respect to a company. PFM may also engage in top-down macro-economic analysis to identify opportunities, whether on a directional or relative value basis, across a wide range of global markets and investment instruments. They may consider economic, political and financial market conditions in seeking to identify attractive investment opportunities. The firm invests in and trades a wide range of investment instruments, including securities, options, ETFs, futures, currencies, derivatives, debt instruments and other assets that are financial instruments. They take both long and short positions in such investment instruments.

Details Hidden

OrbiMed Advisors focuses on investments in the global healthcare industry. The firm invests across the spectrum of life sciences companies from early-stage private biotechnology companies to large, publicly-traded pharmaceutical companies. OrbiMed Advisors manages investments across three strategies: mutual funds, hedge funds and private equity funds. The firm is also known to engage in shareholder activist investment strategies.OrbiMed Advisors' hedge fund strategy invests both long and short in the health sciences sector. OrbiMed employs a global investment approach that provides a broad opportunity set and reduced volatility through diversification. They take long positions primarily in small-cap and mid-cap companies with products with the potential for future 'blockbuster' potential.OrbiMed Advisors' mutual funds also invest globally in health sciences companies. Funds under management include the Eaton Vance Worldwide Health Sciences Fund and the Finsbury Worldwide Pharmaceutical Trust. The Eaton Vance Worldwide Health Sciences Fund is a publicly-offered open-end mutual fund that invests globally in biotechnology and pharmaceutical investment opportunities. The Finsbury Worldwide Pharmaceutical Trust is a closed-end UK Investment Trust which also invests globally in biotechnology and pharmaceutical investment opportunities.The firm's private equity activities focus drug discovery, drug development and medical device companies. The firm invests across all stages of company development with particular emphasis on mid- and later-stage private companies. OrbiMed Advisors is generally the lead investor in their portfolio companies and often takes an active role on those companies' boards of directors.

Details Hidden

Redmile Group invests primarily in U.S. and non-U.S. healthcare companies. While the partnerships and funds generally invest in public equities, these investtments may be in illiquid, publicly-quoted securities, investments may be made in illiquid, publicly-quoted securities. The partnerships or funds may invest in private companies and non-equity asset classes when Redmile Group believes such investments offer a superior risk-reward. The firm may also invest in fields related to healthcare where due diligence shows that the healthcare assets are the driving force behind value creation and may also invest in other sectors from time to time. While Redmile Group mainly invests public equities of healthcare companies, they gennerally have broad and flexible investment authority. To maintain flexibility and capitalize on investment opportunities as they arise, the Redmile Group isn't required to invest any particular percentage of managed portfolios in any particular type of investment or region, and the amount of the portfolios which is invested in any type of investment or which is weighted in different countries or different sectors can change at any time. As such, investments may at any time include long or short positions in U.S. or non-U.S. publicly traded or privately issued common stocks, preferred stocks, stock warrants and rights, bonds, notes or other debentures or debt participations, convertible bonds, convertible preference shares, fund interests, swaps, options (including options on stock market indices), futures contracts, commodities, forward contracts and other securities or financial instruments including those of investment companies.^

Subscribe now to see full details
Recent Transactions
Details Hidden

Puma Biotechnology, Inc. issued Common Stock

Details Hidden

Puma Biotechnology, Inc. issued Common Stock

Details Hidden

Puma Biotechnology, Inc. issued Common Stock

Subscribe now to see full list of recent transations
Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Subscribe now to see full details
Transaction Advisors
Manager

Advised onPuma Biotechnology, Inc. issued Common Stock

Manager

Advised onPuma Biotechnology, Inc. issued Common Stock

Legal Advisor

Advised onPuma Biotechnology, Inc. issued Common Stock

Subscribe now to see 10+ more transaction advisors
Legal Advisor

Advised onPuma Biotechnology, Inc. issued Common Stock

Underwriter

Advised onPuma Biotechnology, Inc. issued Common Stock

Managing Director

Advised onPuma Biotechnology, Inc. issued Common Stock

Subscribe now to see 4+ more transaction advisors
Key Stats and Financials As of 2016
Market Capitalization
$2.52B
Total Enterprise Value
$793M
Earnings Per Share
$-8.29
Revenue
$0
Net Profit
$-276M
EBITDA
$-275M
Total Debt
$0
Total Equity
$210M
TEVNet Income
-2.87x
Debt TEV
0x
Three Year Compounded Annual Growth Rate Of Revenue
0%
Five Year Compounded Annual Growth Rate Of Revenue
0%
Subscribe now to see full financial details
Investors
Details Hidden

Fidelity Management & Research Co.'s (FMR) investment approach is based on a rigorous, fundamental, bottom-up stock selection process. The firm seeks to identify and invest in the stocks of companies with the potential for long-term capital appreciation or companies with hidden or unrealized value.FMR uses a wide variety of investment strategies in managing client assets, including, but not limited to, investments in: stocks and other equity securities; stocks with growth or value characteristics; bonds and other debt securities and repurchase agreements for those securities; and real estate related investments. The firm may participate in short sales, margin transactions, and option writing, including covered options, uncovered options or spreading strategies. FMR invests in US and non-US issuers, including issuers in emerging or frontier markets. They invest in companies with small, medium and large market capitalizations. Investments are allocated across different asset classes, market sectors, maturities, countries, and regions. Investments may be made in the securities of companies engaged in particular industries or market sectors and in a combination of underlying Fidelity funds.Margin may be required in connection with certain client futures and options transactions or in connection with short sales. FMR does not engage in the purchase of securities on margin, except in connection with the clearance and settlement of securities transactions.FMR may engage in swap transactions and swaptions, including interest rate, total return and credit default; written covered call options; and futures transactions, currency spot and forward trading and other currency related derivatives. In addition, FMR may engage in securities lending to parties such as broker-dealers or other institutions.

Details Hidden

T. Rowe Price Associates' investment approach is based on the belief that fundamental proprietary research drives value-added, active investment management. The firm maintains a global research platform that includes interconnected teams of research analysts. Their strategy begins with bottom-up analysis. T. Rowe Price uses both qualitative and quantitative analysis to evaluate investment opportunities. Portfolios are created with a commitment to diversification and a strict attention to valuation appropriate to the chosen investment universe.For their institutional clients, T. Rowe Price Associates maintains multiple active management strategies in equity and fixed-income asset classes. These strategies include: (1) US, global, and international equity mandates including small-, mid- and large-cap, growth, value and core, index-enhanced, as well as sector-specific equity mandates and (2) US, global and international fixed-income mandates including active taxable (core plus, core, enhanced bond), cash management, short-term, high yield, global, emerging markets, municipal and sector-specific fixed-income mandates. In addition, the firm's Private Asset management Group provides balanced, equity and fixed-income investment management services to meet the needs of individuals, trusts, endowments, foundations, institutions, retirement plans and IRAs and other entities.

Subscribe now to see full details
Suppliers
Pfizer, Inc. Medical Support Services | WASHINGTON, DC

Pfizer, Inc. engages in the manufacture of vaccines and injectable biologic medicines. It operates through the Pfizer Innovative Health and Pfizer Essential Health segments. The Pfizer Innovative Health segment focuses on developing and commercializing novel, value-creating medicines, and vaccines for the internal medicine, vaccines, oncology, inflammation and immunology, rare diseases, and consumer healthcare. The Pfizer Essential Health segment comprises of global brands, sterile injectable pharmaceuticals, infusion systems, biosimilars, and Pfizer CentreOne. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

CaligorRx, Inc. Medical Products & Equipment | Secaucus, NJ

Caligor RX, Inc. provides clinical trial supply and logistics services. It manages the regulatory, logistics, and supply chain challenges of sourcing, storing, and distributing investigational drugs for comparator clinical trials and unlicensed medicines for expanded access programs. The firm serves pharmaceutical and biotechnology companies. The company is headquartered in Secaucus, NJ.

Subscribe now to see suppliers for over 2.5 million organizations
Competitors
Novartis AG Pharmaceuticals - Basel, BS

Novartis AG develops, manufactures, and markets healthcare products. It operates through the following segments: Innovative Medicines, Alcon, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Alcon segment researches, develops, manufactures, distributes and sells eye care devices and vision care. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Takeda Pharmaceutical Co., Ltd. Pharmaceuticals - Tokyo, TY

Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Takeda's ethical drugs are marketed in around 100 countries worldwide.

Array BioPharma Inc. Pharmaceuticals - Boulder, Colorado

Array BioPharma, Inc. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, ONT-380 (ARRY-380), ARRY-797, Ipatasertib, Motolimod, Danoprevir, ARRy-614, GDC-0994, and LOXO-101. Its drugs focuses on the treatment of cancer and inflammatory diseases. The company was founded by Kevin Koch, Anthony Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO.